Breaking News

DSM Wins Paranta Bio-Contract

Will provide process development, manufacture at Australian Facility

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

DSM Pharmaceutical Products has signed a biologics contract with Paranta Biosciences under which DSM will provide the process development and cGMP manufacture of Follistatin, Paranta’s lead recombinant human protein, at its Brisbane facility. Financial terms were not disclosed. Alexander Wessels, chief executive officer of DSM Pharmaceutical Products, said, “Working with Paranta is an important milestone for DSM to support the local client base directly from our facility in Australi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters